Alzhéimer, párkinson y… ¿un mismo origen?

¿Y si tanto el alzhéimer y las demás demencias, como el párkinson, el glaucoma, la ELA y quién sabe cuántas implacables condenas más, compartieran un mismo origen? ¿Y si fueran síntomas o distintas manifestaciones de la misma condición subyacente, cuyo talón de Aquiles, precisamente, son los niveles bajos de glucosa y de insulina en sangre que nos regala la dieta cetogénica… lo que explicaría que esta, efectivamente, funcione?

Contenido adicional restringido. Para acceder a él, elige tu recorrido y adquiere tu dorsal.

¿Quieres oír los episodios antes que nadie? Suscríbete al podcast en ivoox o escúchalos en Amazon MusicApple Podcasts, Spotify Podcasts y SoundCloud.

¿Quieres, además, oírlo sin anuncios y descargarte la transcripción referenciada? ¡Consigue tu dorsal o tu pase VIP para la maratón y regodéate en las ketofilias VIP’s!


Referencias

(por orden de aparición)

Si quisieras ahondar en el tema o también ansías blindar tu cerebro a las despiadadas demencias (y ponérselo difícil a las demás enfermedades neurodegenerativas), echa un ojo al programa Blinda tu cerebro (que está disponible en libro digital o papel, cursillo de vídeo presentaciones y audiolibro en formato podcast semanal).

Zhu, H., Bi, D., Zhang, Y., Kong, C., Du, J., Wu, X., Wei, Q., & Qin, H. (2022). Ketogenic diet for human diseases: The underlying mechanisms and potential for clinical implementations. Nature: Signal Transduction and Targeted Therapy, 7(1), 11. https://doi.org/10.1038/s41392-021-00831-w

No dejes de perderte por la web de la Dra. Ede («Diagnóstico Dieta: donde la nutrición se encuentra con el sentido común») si te defiendes con el inglés. Es una keto-mina de oro rigurosa, pero inspiradora y mordaz.

 Ede, G. (2019). Parkinson’s, Alzheimer’s, and the New Science of Hope | Psychology Today. https://www.psychologytoday.com/gb/blog/diagnosis-diet/201906/parkinsons-alzheimers-and-the-new-science-hope

Krashia, P., Nobili, A., & D’Amelio, M. (2019). Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer’s Disease. Frontiers in Molecular Neuroscience, 12, 123. https://doi.org/10.3389/fnmol.2019.00123

Bredesen, D. (2021). El Fin del Alzhéimer: El Primer Protocolo Para Mejorar La Cognición Y Revertir El Deterioro Cognitivo a Cualquier Edad. Disponible en Amazon.

Daulatzai, M. A. (2017). Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s disease. Journal of Neuroscience Research, 95(4), 943-972. https://doi.org/10.1002/jnr.23777

Dineley, K. T., Jahrling, J. B., & Denner, L. (2014). Insulin Resistance in Alzheimer’s Disease. Neurobiology of disease, 72PA, 92-103. https://doi.org/10.1016/j.nbd.2014.09.001

Du, A. T., Schuff, N., Amend, D., Laakso, M. P., Hsu, Y., & Weiner, M. W. (2001). Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 71(4), 441. https://doi.org/10.1136/jnnp.71.4.441

 Sterling, N. W., Lewis, M. M., Du, G., & Huang, X. (2016). Structural Imaging and Parkinson’s Disease: Moving Toward Quantitative Markers of Disease Progression. Journal of Parkinson’s Disease, 6(3), 557-567. https://doi.org/10.3233/JPD-160824

Tan, J., Digicaylioglu, M., Wang, S. X. J., Dresselhuis, J., Dedhar, S., & Mills, J. (2019). Insulin attenuates apoptosis in neuronal cells by an integrin-linked kinase-dependent mechanism. Heliyon, 5(8), e02294. https://doi.org/10.1016/j.heliyon.2019.e02294

Hart, B. (2022). Have Scientists Been Wrong About Alzheimer’s for Decades? Intelligencer. https://nymag.com/intelligencer/2022/08/have-scientists-been-wrong-about-alzheimers-for-decades.html

Bredesen D. E. (2014). Reversal of cognitive decline: a novel therapeutic program. Aging, 6(9), 707–717. https://doi.org/10.18632/aging.100690

Piller, C. (2022). Potential fabrication in research images threatens key theory of Alzheimer’s disease. (2022). Science. Vol 377, Issue 6604. https://www.science.org/content/article/potential-fabrication-research-images-threatens-key-theory-alzheimers-disease

 Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006). A specific amyloid-β protein assembly in the brain impairs memory. Nature, 440(7082), 352-357. https://doi.org/10.1038/nature04533

 Tan, R. H., Kril, J. J., Yang, Y., Tom, N., Hodges, J. R, … & Halliday, G. M. (2017). Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 9, 10-20. https://doi.org/10.1016/j.dadm.2017.05.005

Medeiros, R., Baglietto-Vargas, D., & LaFerla, F. M. (2011). The role of tau in Alzheimer’s disease and related disorders. CNS Neuroscience & Therapeutics, 17(5), 514-524. https://doi.org/10.1111/j.1755-5949.2010.00177.x

Riederer, P., Berg, D., Casadei, N., Cheng, F., Classen, J., … & Monoranu, C. (2019). α-Synuclein in Parkinson’s disease: Causal or bystander? Journal of Neural Transmission, 126(7), 815-840. https://doi.org/10.1007/s00702-019-02025-9

Guo, L., Salt, T. E., Luong, V., Wood, N., Cheung, W., … & Cordeiro, M. F. (2007). Targeting amyloid-beta in glaucoma treatment. Proceedings of the National Academy of Sciences of the United States of America, 104(33), 13444-13449. https://doi.org/10.1073/pnas.0703707104

Chiasseu, M., Cueva Vargas, J. L., Destroismaisons, L., Vande Velde, C., Leclerc, N., & Di Polo, A. (2016). Tau Accumulation, Altered Phosphorylation, and Missorting Promote Neurodegeneration in Glaucoma. The Journal of Neuroscience, 36(21), 5785-5798. https://doi.org/10.1523/JNEUROSCI.3986-15.2016

 Faiq, M. A., & Dada, T. (2017). Diabetes Type 4: A Paradigm Shift in the Understanding of Glaucoma, the Brain Specific Diabetes and the Candidature of Insulin as a Therapeutic Agent. Current Molecular Medicine, 17(1), 46-59. https://doi.org/10.2174/1566524017666170206153415

 Watson, G. S., Peskind, E. R., Asthana, S., Purganan, K., Wait, C., Chapman, D., Schwartz, M. W., Plymate, S., & Craft, S. (2003). Insulin increases CSF Abeta42 levels in normal older adults. Neurology, 60(12), 1899-1903. https://doi.org/10.1212/01.wnl.0000065916.25128.25

Galizzi, G., & Di Carlo, M. (2022). Insulin and Its Key Role for Mitochondrial Function/Dysfunction and Quality Control: A Shared Link between Dysmetabolism and Neurodegeneration. Biology, 11(6), 943. https://doi.org/10.3390/biology11060943

Mullins, R. J., Diehl, T. C., Chia, C. W., & Kapogiannis, D. (2017). Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease. Frontiers in Aging Neuroscience, 9, 118. https://doi.org/10.3389/fnagi.2017.00118

Choi, A., Hallett, M., & Ehrlich, D. (2021). Nutritional Ketosis in Parkinson’s Disease—A Review of Remaining Questions and Insights. Neurotherapeutics, 18(3), 1637-1649. https://doi.org/10.1007/s13311-021-01067-w

Hsieh, C.-F., Liu, C.-K., Lee, C.-T., Yu, L.-E., & Wang, J.-Y. (2019). Acute glucose fluctuation impacts microglial activity, leading to inflammatory activation or self-degradation. Nature, 9(1), 840. https://doi.org/10.1038/s41598-018-37215-0

Fournet, M., Bonté, F., & Desmoulière, A. (2018). Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging. Aging and Disease, 9(5), 880-900. https://doi.org/10.14336/AD.2017.1121

Kim, B., & Feldman, E. L. (2015). Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Experimental & Molecular Medicine, 47(3), e149. https://doi.org/10.1038/emm.2015.3

Sasaki-Hamada, S., Sanai, E., Kanemaru, M., Kamanaka, G., & Oka, J.-I. (2022). Long-term exposure to high glucose induces changes in the expression of AMPA receptor subunits and glutamate transmission in primary cultured cortical neurons. Biochemical and Biophysical Research Communications, 589, 48-54. https://doi.org/10.1016/j.bbrc.2021.11.108

Krashia, P., Nobili, A., & D’Amelio, M. (2019). Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer’s Disease. Frontiers in Molecular Neuroscience, 12, 123. https://doi.org/10.3389/fnmol.2019.00123

Song, J., & Kim, J. (2016). Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease. Frontiers in Aging Neuroscience, 8. https://www.frontiersin.org/articles/10.3389/fnagi.2016.00065